Literature DB >> 1859521

Monosialoganglioside in subarachnoid hemorrhage.

I Papo1, A Benedetti, A Carteri, G A Merli, S Mingrino, R Bruno.   

Abstract

We studied 119 patients with disturbance of consciousness following subarachnoid hemorrhage, due mostly to verified aneurysm rupture, admitted to five Italian neurosurgical departments over 18 months. Level of consciousness as assessed by score on the Glasgow coma Scale ranged from 8 to 14 before the beginning of treatment; level of consciousness was assessed again 7, 14, and 21 days later. Patients were randomly allocated to treatment with monosialoganglioside or placebo according to a double-blind experimental design. The two treatment groups were homogeneous at entry with regard to the main clinical parameters. Both groups improved, but the rate and degree of improvement were greater in the monosialoganglioside-treated group. The difference was significant on days 14 (p = 0.04) and 21 (p = 0.02). Our results seem to confirm the hypothesis that monosialoganglioside reduces brain edema and provides nonspecific neuronal membrane protection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859521     DOI: 10.1161/01.str.22.1.22

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

1.  Gangliosides and neurological diseases.

Authors:  M Alter
Journal:  BMJ       Date:  1993-01-16

2.  The Therapeutic Role of Gangliosides in Neurological Disorders.

Authors:  J S Schneider
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

Review 3.  Gangliosides. Their role in clinical neurology.

Authors:  E Nobile-Orazio; M Carpo; G Scarlato
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 4.  Gangliosides: Treatment Avenues in Neurodegenerative Disease.

Authors:  Pierre J Magistretti; Fred H Geisler; Jay S Schneider; P Andy Li; Hubert Fiumelli; Simonetta Sipione
Journal:  Front Neurol       Date:  2019-08-06       Impact factor: 4.003

Review 5.  GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration.

Authors:  Elena Chiricozzi; Giulia Lunghi; Erika Di Biase; Maria Fazzari; Sandro Sonnino; Laura Mauri
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.